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The purpose of this study was to determine the maximum tolerated dose (MTD) of gemcitabine when given
concurrently with standard radiotherapy for the treatment of chest wall recurrences, and to compare actuarial rates of local-regional
control with those achieved in historical controls. Patients with unresectable chest wall recurrences were enrolled in a phase I trial









week. Radiotherapy was delivered to the chest wall and regional nodes to a total of 60 to 70 Gy in 2 Gy daily fractions. Treatment
toxicity was assessed and a comparison of treatment outcome was performed between study patients and historical groups treated
with either radiotherapy alone or excision followed by radiotherapy. The dose-limiting toxicities of neutropenia and thrombocytopenia









week. Myelosuppression and skin desquamation were commonly observed. Actuarial rates of local-regional control were 100%,















is delivered concurrently with radiotherapy for unresectable chest wall failures. This novel approach suggests excellent local-
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 chest wall recurrence of breast cancer is defined as the
appearance of tumor in the skin, subcutaneous tissue,
or muscles of the chest wall following mastectomy. It may be
associated with nodal failures involving the supraclavicular,
axillary, and/or rarely the internal mammary regions.
The incidence of an isolated breast cancer chest wall
recurrence with or without regional nodal involvement
after mastectomy has been reported to be from 5% to 30%
in several series, largely dependent upon the extent of nodal
involvement and the size of the primary tumor (1–3).
The standard treatment for an isolated local or local-
regional failure after mastectomy is radiotherapy, with
a preceding surgical resection when feasible. In general,
for patients with smaller lesions that are amenable to a
complete resection, all gross disease is excised prior to
proceeding with local-regional radiotherapy. These patients
have an increased probability of local control, and in most
cases survival, when compared to those with larger
unresectable lesions (4–8).
Current treatment for patients with unresectable
chest wall recurrences, however, is mainly restricted to
radiotherapy alone. Several centers have reported 5-year
rates of local failure as high as 66 to 76% in patients treated
with full-dose radiotherapy alone versus 43 to 52% observed
in those treated with excision followed by radiotherapy.
Unfortunately local control at times is not durable even
for those patients with surgically resectable recurrences
(4,6), and uncontrolled local-regional disease can adversely
affect quality of life (9). Thus sustained palliation remains
an important therapeutic goal, and a chest wall recurrence
of breast cancer represents an excellent clinical model










-difluorodeoxycytidine [dFdC]) is a
deoxycytidine analogue that elicits cancer cell death through
its incorporation into DNA and inhibition of deoxynucleotide
synthesis. Antitumor activity of gemcitabine has been
tested in culture on multiple cell lines, and drug efficacy
has been observed in human xenograft studies involving
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breast, lung, head and neck, colon, and ovarian cancers (10).
Recent phase II trials have been conducted successfully
in a variety of solid tumors, including breast cancer
(11). In addition, radiation-sensitization properties of
gemcitabine have been recently demonstrated at non-
cytotoxic drug levels in several solid tumor cell lines in
vitro, including the human breast cancer cell line MCF-7
(12–14). Therefore, with both proven cytotoxic and
radiation-sensitizing activities in breast cancer, gemcitabine
represents an excellent candidate drug for radiation-
sensitizing studies in the treatment of unresectable
chest wall failures that have been historically resistant to
radiotherapy alone.
The primary objective of this phase I trial was to
determine the maximum tolerated dose (MTD) of once-
a-week gemcitabine and its dose-limiting toxicity (DLT)
when administered concurrently with standard radiation
in patients with unresectable chest wall recurrences. A
secondary objective was to assess and compare the actuarial
rates of local-regional control achieved with gemcitabine
and radiotherapy with the rates observed in historical






After obtaining Institutional Review Board approval,
all patients with unresectable local-regional recurrence of
breast cancer following mastectomy who signed informed
consent forms were eligible to participate in this phase I trial.
Histopathologic confirmation of a chest wall recurrence
with at least 1 cm of gross unresectable disease with or
without nodal involvement was required. Patients with
synchronous distant metastases were eligible as long as
their life expectancy was at least 4 months. No concurrent
chemotherapy other than gemcitabine was allowed, with
a mandatory washout time of at least 4 weeks from any
previous chemotherapy or hormonal therapy. Additional





performance score of 60 or greater, freedom from any
medical comorbidity that would limit survival to less than
2 years, and adequate organ function as demonstrated by






























g/dl, creatinine less than 2.0 mg/
dl, aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) less than three times the upper limits
of normal, total bilirubin less than 2.0 mg/dl, prothrombin
time (PT) less than 14, and partial thromboplastin time
(PTT) less than 40.
Exclusion criteria consisted of any regional node involve-
ment in the absence of chest wall failure and a history of any





Dose escalation of gemcitabine was performed while
delivering a standard dose of radiotherapy. A starting




/week (approximately 25% of the
MTD of gemcitabine when used alone) was chosen for
the study. Gemcitabine was administered via once-a-week




/min. This rate was based
on clinical and in vitro studies demonstrating that the
accumulation rate of difluorodeoxycytidine triphosphate
(dFdCTP) in mononuclear and leukemia cells was satur-










steady-state plasma levels at this range, making this
schedule attractive for radiosensitizing studies (15,16).
Preclinical data and recent clinical trials demonstrated that
gemcitabine could radiosensitize tumor cells at concentra-




M (14,17,18). Thus the constant dose
rate infusion was felt to provide plasma levels well in
excess of those needed for radiosensitization. The dose was




/week increments in successive
cohorts of three patients until the DLT was observed.
On days when gemcitabine was given, radiotherapy was
delivered 4 hours after initiation of the drug infusion. This
was based on preclinical data suggesting radiosensitization
could occur as early as 4 hours after treatment, and lasting
up to 2 days (17).
Radiotherapy was administered to the chest wall and
regional nodes using techniques previously described (19).
All patients had a pretreatment computed tomography
(CT) scan with contrast to assess the extent of chest wall
and regional nodal involvement. For patients with chest
wall disease with or without supraclavicular disease, both
chest wall and supraclavicular fossa regions were irradiated.
If the axillary and/or internal mammary nodes were
clinically involved, these nodal sites were included in the
treatment volume. The entire chest wall was irradiated to
50 Gy utilizing opposed lateral tangential fields; 6 to 10
MV photon beams were used with either 0.5 cm of bolus
every day or 1 cm of bolus every other day. For patients with
no palpable supraclavicular disease, the supraclavicular
fossa received 46 to 50 Gy to a depth of 3 cm. For patients
with supraclavicular involvement, a minimum dose of
50 Gy and maximum dose of 60 Gy was prescribed.
Additional boosts of 10 to 20 Gy were administered to the









beams, with the final dose dependent upon tumor bulk
(20).
Toxicity grading was assessed using the Southwest
Oncology Group (SWOG) Toxicity Criteria. DLT was
defined as any grade 4 hematologic toxicity, grade 3
nonhematologic toxicity (except for alopecia, nausea,
vomiting, or desquamation secondary to radiotherapy),
or grade 3 dermatitis or desquamation appearing within
the first 3 weeks of radiation. On-treatment visits with
the treating physician as well as physical examinations
and laboratory studies, including complete blood count,
biochemistry panel with liver function tests, and urinalysis,
were performed on a weekly basis for monitoring of
toxicity during therapy.
Dose escalation of gemcitabine was performed after
three patients treated at the same dose level were observed
for a minimum of 4 weeks after completion of their treat-
ments. If a DLT was encountered in one of three patients,
then three additional patients were treated at the same
dose; if only one of six patients experienced a DLT, then
the subsequent group was treated at the next higher dose
level. If the DLT was encountered in more than one of
three to six patients at any dose level, the MTD would
be declared as having been exceeded and dose escalation
was terminated. The MTD was therefore defined as the
dose level below which more than one of three to six
patients developed a DLT.
If a DLT occurred, a break in the scheduled gemcitabine
treatment was initiated until the toxicity had declined to
grade 2 or less. Gemcitabine was then resumed at the
next lower dose level. If a DLT occurred following a dose
reduction, the patient was removed from the study. A dose
reduction was initiated for any grade 2 hematologic tox-
icity or grade 3 dermatitis appearing after the first 3 weeks
of radiation that was refractory to supportive measures.
Withholding a dose was required for any grade 3 hema-
tologic toxicity. Once a dose reduction or withholding
occurred, the next dose was resumed at the full level.
Radiation treatments continued without interruption except
for a grade 3 skin desquamation not responsive to
supportive measures.
Patients were seen in follow-up at 1 month after com-
pletion of their treatments. Clinical assessment of toxicity
consisting of history, physical examination, and laboratory
studies was performed. Patients were then followed every
2 months to assess tumor response and toxicity. Response
grading was as follows: complete response (CR), no
evidence of tumor; partial response (PR), at least a 50%
decrease in tumor size based on physical examination and
radiologic studies; stable disease, no change in tumor size;
and progression, an increase of at least 25% in the size of
measured lesions or the appearance of new lesions.
In addition, two historical cohorts of patients—those
with unresectable chest wall failures treated with radio-
therapy alone and those with resectable chest wall lesions
treated with excision and postoperative radiotherapy—
were identified retrospectively from our institutional breast
cancer registry by applying the same exclusion criteria
used in our prospective phase I study. More specifically,
the search criteria included any pre- or postmenopausal
women with a history of breast cancer treated with mas-
tectomy and/or systemic therapy without postmastectomy
irradiation who underwent salvage radiotherapy with
or without surgical excision for a chest wall recurrence.
Kruskal–Wallis and Fisher exact chi-square tests were
utilized to discern any differences in the baseline clinical
characteristics among the three groups of patients. Crude
rates of local-regional control for each treatment group
were ascertained. Actuarial local-regional control curves
were then generated utilizing the Kaplan–Meier technique,
and overall differences among the three groups were







Only six patients were required to reach the DLT, as
discussed below. Three patients were treated at each dose




/week of gemcitabine. All
patients were assessable for treatment-related toxicity and
tumor control. Two groups of historical controls con-
sisting of a total of 32 patients were identified from our
computerized institutional breast cancer registry. Control
group 1 consisted of eight patients with unresectable chest
wall recurrences treated with radiotherapy alone; control
group 2 consisted of 24 patients with resectable chest wall
recurrences treated with excision followed by radiotherapy.
Of note, none of these patients had any missing data that
was required for the comparative analysis.
Clinical characteristics for each group are shown in
Table 1. The protocol and historical control 1 groups were
similar except for treatment with a greater number of
different chemotherapy regimens and less hormonal therapy,
larger recurrent tumor burden, and a higher incidence
of synchronous distant metastasis at the time of recurrent
disease diagnosis among the protocol patients. Patients in
historical control group 2 were more likely to have better
Karnofsky Performance Status (KPS), present with earlier
stages of disease prior to mastectomy, and less likely to
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have received chemotherapy in the past when compared
to the other two groups. These patients were also more
likely to have less tumor burden as manifested by smaller,
solitary recurrences limited to the chest wall without syn-
chronous distant metastases. Overall the protocol patients
had the most aggressive chest wall failures, as evidenced
by extensive local tumor burden and a higher percentage
of synchronous distant metastases prior to initiation of
gemcitabine and radiotherapy when compared with either
of the two historical cohorts.
Median follow-up for the protocol, historical control
1, and historical control 2 patients was 2 years (range
0.1–3.1 years), 4 years (range 0.1–6.9 years), and 6 years




Dose-limiting toxicities occurred at the second planned




/week in two of three patients. One
patient experienced grade 4 thrombocytopenia as well
as grade 3 neutropenia, while the other patient sustained
a grade 4 neutropenia. Both patients were eventually
removed from the study. The first patient experienced
further neutropenia despite reduction and withholding of
subsequent doses, and the latter patient experienced
persistent grade 3 neutropenia as well a grade 3 radiation-
induced skin desquamation refractory to conservative
measures. The remaining patient did not incur a DLT and
was able to receive six cycles of gemcitabine, with one dose
reduction and one dose held due to hematologic toxicity.
All three patients were able to complete their scheduled
total radiotherapy doses of 70 Gy, except for one patient
who experienced significant grade 3 skin dermatitis near
the end of her treatments and discontinued radiotherapy
at 68 Gy.





was encountered. All three patients were able to complete
the planned gemcitabine cycles (two received six cycles
and one received five cycles). Two patients each required




/week and one dose
to be held for hematologic toxicity according to the
protocol guidelines. The remaining patient, who had





experienced both hematologic and radiation-related skin
toxicities, complicated by a transient idiosyncratic drug
rash that necessitated four of her doses be reduced. She was,
however, able to receive a total of five cycles of gemcitabine
Table 1. Comparison of Clinical Characteristics by Study Group
 
Protocol group (n = 6) Control group 1 (n = 8) Control group 2 (n = 24) p
Age
Median (years) 59 61 53 0.35
Range (years) 44–79 52–77 35–86
KPS
Median 80 80 90 0.01
Range 60–90 70–90 80–90
Primary tumor (stage)
0 0 (0%) 0 (0%) 2 (8%)
I 0 (0%) 1 (13%) 12 (50%)
II 4 (67%) 5 (64%) 10 (42%)
III 2 (33%) 2 (23%) 0 (0%) 0.01
Patients receiving adjuvant chemotherapy 5 (83%) 3 (38%) 7 (29%) 0.06
No. of patients receiving different chemotherapy regimens
Median 2 0 0 <0.001
Range 0–3 0–1 0–1
Patients receiving adjuvant hormonal therapy 2 (33%) 5 (63%) 6 (25%) 0.18
Disease-free interval
Median (years) 5.0 4.3 3.7 0.89
Range (years) 0.4–7.3 1.0–24.0 0.4–18.7
Site of local-regional recurrent disease
Chest wall only 2 (33%) 3 (37%) 23 (96%)
Chest wall + regional nodesa 4 (67%) 5 (63%) 1 (4%) <0.001
Size (area) of local-regional recurrent disease
Median (cm2) 29.3 11.0 1.0 <0.001
Range (cm2) 2.4–144 1.5–40 0.2–16
Number of recurrent lesions
Solitary 0 (0%) 0 (0%) 21 (88%)
Multiple 6 (100%) 8 (100%) 3 (12%) <0.001
Synchronous distant metastases 3 (50%) 1 (12%) 0 (0%) 0.01









and complete her radiotherapy. All three patients
completed the full dose of 50 Gy to the chest wall and
supraclavicular regions. They also received boost doses of
an additional 20 Gy to sites of gross disease, except for one
patient who withdrew from the study 3 days prior to the
end of her treatments due to progressing systemic disease
and declining performance status.
The toxicity profiles at both dose levels are shown in
Table 2. In general, myelosuppression and the expected
grade 3 radiotherapy-induced skin desquamation were
most commonly observed. Some experienced mild nausea
and fatigue, but no mucositis, emesis, diarrhea, pneumonitis,
hepatotoxicity, proteinuria, flu syndrome, fever, or alopecia
was noted. One patient incurred an idiosyncratic drug rash
that resolved without intervention, while another patient
experienced mild transitory elevations in AST and ALT




All six patients had significant clinical responses by the
end of their treatments; three achieved complete responses
while three experienced partial responses. Within 1 month
of follow-up, all six patients had achieved complete
regression of their treated local-regional disease based on
clinical examination.
Thus the crude rate of local-regional control was
100% (6/6) in protocol patients treated with gemcitabine
and radiotherapy. These results compared favorably to
the crude rates of 50% (4/8 patients) and 83% (20/24
patients) observed in the historical cohorts with unresec-
table recurrences treated with radiotherapy alone and
resectable failures treated with excision followed by
radiotherapy, respectively. Figure 1 shows a bar chart of





Actuarial rates of local-regional control were then
assessed for the protocol patients (gemcitabine and radio-
therapy) and compared to those of the two historical
cohorts (radiotherapy alone; excision and radiotherapy)
using the Kaplan–Meier method. Results are plotted in
Figure 2. The radiotherapy alone group did worse with
time, while the gemcitabine and radiotherapy group and
excision and radiotherapy group fared similarly. The
difference in local-regional control among the three








Isolated chest wall recurrences not amenable to gross
resection pose a significant challenge for the treating
radiation oncologist. These patients are at high risk of either
persistent disease or recurrence following standard radio-
therapy. Retrospective series have reported 5-year actuarial
rates of local-regional recurrences as high as 76% with
radiotherapy alone, despite optimal treatment planning
and delivery (4,6), leading to compromised quality of
Table 2. Maximal Acute and Late Toxicities at 300
and 450 mg/m2/week of Gemcitabine with Concurrent
Radiotherapy
 
300 mg/m2/week (n = 3) 450 mg/m2/week (n = 3) 
Grade 1 2 3 4 1 2 3 4
Neutropenia — 1 2 — — — 2 1a
Thrombocytopenia — 1 — — — — — 1a
Anemia 3 — — — 1 2 — —
Desquamation — — 3 — — — 3 —
Drug rash — 1 — — — — — —
Elevated AST 1 — — — — — — —
Elevated ALT 1 — — — — — — —
Nausea 2 — — — 1 — — —
Fatigue 1 1 — — — 1 — —
aDose-limiting toxicity.
Figure 1. Bar chart of the crude rates of local-regional control using
gemcitabine and radiotherapy, radiotherapy alone, and excision and
radiotherapy for chest wall recurrences.
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life (9). Thus effective local-regional treatment would
be invaluable in this subset of recurrent breast cancer
patients.
Although radiation dose escalation has been associated
with increased tumor control, normal tissue tolerance
limits delivery of the high doses required to sterilize bulky
disease. Thus, due to the constraints of radiotherapy alone,
the addition of concurrent chemotherapy to radiotherapy
is a logical approach. The use of combined modality treat-
ments is increasingly more common in the treatment of
many solid tumors. Theoretical benefits of this approach
include potential sterilization of systemic disease, as well
as combined cytoreduction of local-regional tumor.
To our knowledge, this is the first clinical trial that has
investigated the feasibility of delivering concurrent low-dose
gemcitabine or any radiosensitizer with standard radio-
therapy in breast cancer patients with unresectable chest
wall recurrences. Gemcitabine is a drug with cytotoxic
activity in breast cancer and radiation-sensitizing proper-
ties, both beneficial in the treatment of unresectable chest
wall recurrences. Our study shows that for unresectable
chest wall recurrences, the maximum tolerated dose of




/week when given once a
week with concurrent standard radiotherapy. Studies of
gemcitabine given concomitantly with radiotherapy in





/week (21). However, this dose exceeded
the MTD when given once a week with radiotherapy in
patients with head and neck cancer (18). The low dose
required in the current series probably reflects the extent
of prior treatment with systemic therapies and limited
bone marrow reserve. Nonetheless, there was excellent
response at this dose, and the plasma concentrations
exceeded the in vitro radiosensitizing concentration by at
least 400-fold, suggesting that clinical benefit may also be
achieved at lower doses for this group of patients.
Our study demonstrates that this novel regimen
can be delivered safely for treatment of unresectable
chest wall recurrences. The DLT, observed in two of the





myelosuppression. Otherwise the most common toxicity
encountered during treatment was the expected grade 3
skin dermatitis secondary to radiotherapy occurring by
the end of therapy. All patients responded to supportive
measures and did not require a break in their radiotherapy,





of gemcitabine. Other than the hematologic and skin-
related toxicities, there were no other significant side
effects except for a grade 2 idiosyncratic drug rash
observed in one patient. All six patients were otherwise
able to tolerate and complete their combined modality
treatments as planned in accordance with the protocol
guidelines.
A limited analysis of early treatment outcomes revealed
that the protocol patients experienced excellent rates
of local-regional control, as all six patients achieved
complete response within 1 month of therapy. These results
compared favorably to those of patients with unresectable
failures treated traditionally with radiotherapy alone.
When the protocol patients were compared to another
group of historical patients with prognostically more
favorable recurrences that were resectable and treated
with postoperative radiotherapy, the local-regional control
of the protocol patients was approximately equivalent if
not better, although median follow-up was shorter and
patient numbers were extremely limited in the protocol
group. These limitations would suggest cautious inter-
pretation of our results, but it should be noted that the
favorable outcome observed in the present series occurred
despite a greater documented tumor burden in the protocol
patients when compared to the other two historical
Figure 2. Actuarial estimates of local-regional control with gemcita-










cohorts. Thus chest wall irradiation with concurrent
gemcitabine, a drug which has both cytotoxic and radiation-
sensitizing properties, appears to have the potential to
improve local-regional outcome, and formal study using









radiotherapy can be safely administered for unresectable
chest wall recurrences. Toxicities were mainly limited
to myelosuppression and expected, yet well-tolerated,
radiotherapy-induced moist desquamation. Early results
using this regimen suggest high rates of local-regional
control in patients with unresectable disease comparable to
rates achieved in historical controls treated with complete
excision followed by comprehensive radiotherapy. This
novel approach of combining gemcitabine with radiother-
apy may offer better local control when compared to
radiotherapy alone for unresectable recurrences. A phase
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